1. Home
  2. SGHT vs JCE Comparison

SGHT vs JCE Comparison

Compare SGHT & JCE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Sight Sciences Inc.

SGHT

Sight Sciences Inc.

HOLD

Current Price

$4.33

Market Cap

235.0M

Sector

Health Care

ML Signal

HOLD

Logo Nuveen Core Equity Alpha Fund of Beneficial Interest

JCE

Nuveen Core Equity Alpha Fund of Beneficial Interest

HOLD

Current Price

$16.16

Market Cap

252.8M

Sector

Finance

ML Signal

HOLD

Company Overview

Basic Information
Metric
SGHT
JCE
Founded
2011
N/A
Country
United States
United States
Employees
N/A
N/A
Industry
Medical Specialities
Trusts Except Educational Religious and Charitable
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
235.0M
252.8M
IPO Year
2021
2007

Fundamental Metrics

Financial Performance
Metric
SGHT
JCE
Price
$4.33
$16.16
Analyst Decision
Buy
Analyst Count
7
0
Target Price
$9.08
N/A
AVG Volume (30 Days)
298.9K
37.1K
Earning Date
05-06-2026
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
28.16
N/A
EPS
N/A
N/A
Revenue
$77,363,000.00
N/A
Revenue This Year
$11.67
N/A
Revenue Next Year
$10.39
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.81
$13.99
52 Week High
$9.24
$16.31

Technical Indicators

Market Signals
Indicator
SGHT
JCE
Relative Strength Index (RSI) 55.08 65.24
Support Level $3.29 $15.57
Resistance Level $5.25 $16.24
Average True Range (ATR) 0.30 0.20
MACD 0.04 0.02
Stochastic Oscillator 38.41 79.66

Price Performance

Historical Comparison
SGHT
JCE

About SGHT Sight Sciences Inc.

Sight Sciences Inc is an ophthalmic medical device company focused on the development and commercialization of surgical and nonsurgical technologies for the treatment of prevalent eye diseases. The company operates through two segments: Interventional Glaucoma, which generates the majority of revenue and includes the OMNI Surgical System family of products and the SION Surgical Instrument used in minimally invasive glaucoma surgery to reduce intraocular pressure in adult patients with open-angle glaucoma; and Interventional Dry Eye, which includes the TearCare System, an interventional device designed to melt and facilitate the removal of meibomian gland obstructions and restore gland functionality in adult patients with evaporative dry eye disease.

About JCE Nuveen Core Equity Alpha Fund of Beneficial Interest

Nuveen Core Equity Alpha Fund is a diversified closed-end management investment company. Its investment objective is to seek attractive total return with less volatility than the S&P 500 Index. The Fund invests in a portfolio of actively managed large-capitalization U.S. common stocks, using the sub-adviser's proprietary quantitative process designed to provide the potential for long-term outperformance. Additionally, the Fund seeks to reduce the volatility of its returns relative to the returns of the Equity Portfolio over extended periods by writing (selling) index call options and/or call options on custom baskets of securities.

Share on Social Networks: